Clinical Trial Update: Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating alternating thalidomide and lenalidomide therapy plus rituximab (ThRiL) as initial treatment for chronic lymphocytic leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• Thalidomide (thalidomide)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-08-26